Pharmacopoeia

A pharmacopeia is an information resource and an official publication that gathers together descriptions of how many different pharmaceuticals can be identified, along with information on their properties, effects, and uses. The entity publishing this information is usually either a professional organization devoted to medical care or a state or national government seeking to compile drug data for the safety of those living in the region. The word itself is Greek in origin and can be translated roughly as “the making of drugs.” There are examples of pharmacopeia dating as far back as the time of the ancient Egyptians, Greeks, and Romans. One of these was written by the Greek scholar Pedanius Dioscorides, and is called De Materia Medica (around 50 CE). De Materia Medica has proven to be an incredibly long-lived work and was regularly in use as a reference as recently as the seventeenth century. Other well-known works include the surgical treatise Edwin Smith Papyrus from Egypt and a medicine-related publication written by Pliny the Elder. In the United States, the Food and Drug Administration (FDA) uses the standards of the United States Pharmacopeia (USP). The World Health Organization (WHO) publishes The International Pharmacopoeia. 

Brief History

Pharmacopeias are intended to serve several different functions in support of public health. The primary purpose served is to establish standards for the composition and quality of medicines within the regional scope covered by the pharmacopeia, which could be an entire country or even a multinational region such as Europe. Because the pharmacopeia’s description of a medicine conclusively defines what compounds are to be included within a drug, drug manufacturers have a standard that they are held to. Without this, an unscrupulous pharmaceutical manufacturer could substitute cheaper, less effective, or completely nonstandard ingredients into its formulation for a drug, which could result in consumers purchasing the drug under the assumption that it has been manufactured according to traditional practices and standards.

Pharmacopeias also support trade in pharmaceutical products. This type of trade is particularly important in the modern, globalized economy, where ingredients for a medication might come from three different countries, be combined in a fourth country, and then transported to a fifth country for sale and consumption. Each of these countries represents a separate set of regulations and standards for the production of medicines, so there is a great need for a uniform set of standardized definitions to make it possible for agents in the pharmaceuticals market to conduct business with one another.

Overview

In the United States, the United States Pharmacopeia (USP) is a nonprofit organization that was founded in 1820 in order to promulgate drug standards. The USP does this in conjunction with the National Formulary (NF). The USP has trademarked its USP-NF label to ensure that only drugs and drug components that follow the requirements of the USP are permitted to be sold under the USP-NF label. This recognized standard gives consumers an independent stamp of approval that they can trust instead of having to rely on drug manufacturers’ representations. There is also a legal component to the USP because the Food and Drug Administration (FDA) uses the standards of the USP to identify drugs that it describes as adulterated. Adulterated medicines may not be sold under FDA regulations, so by enforcing the USP requirements, the FDA is able to protect consumers by banning nonstandard drugs.

One of the greatest challenges faced by the organizations charged with developing and maintaining pharmacopeia is the rapid rate and distributed nature of drug development and research. Companies and university research facilities all around the world are constantly working to develop new medications to treat a vast array of medical conditions. As these drugs navigate through the approval processes within their particular jurisdiction, the pharmacopeia must struggle to keep up with the frenetic pace being set by profit-driven companies with substantial private funding. 

This situation is further complicated in some countries, where the regulatory power of the pharmacopeia is less clearly established than in the United States. In the United Kingdom, the British Pharmacopoeia (BP) sets legally enforceable standards for medicinal substances within the framework of the Human Medicines Regulations 2012, and as established by the Medicines Act 1968. The BP contains entries for substances beyond commercially manufactured drugs, such as gum arabic, beeswax, and linseed oil. It functions as the United Kingdom’s official pharmacopeia, providing legally enforceable quality standards that support regulatory oversight by the Medicines and Healthcare products Regulatory Agency (MHRA). The BP undergoes annual revisions, maintaining its established legal foundation in the UK medical regulation. Pharmaceutical manufacturers in the United Kingdom must adhere to BP standards, which provide consistent quality benchmarks rather than excessive latitude.

The World Health Organization has published The International Pharmacopoeia (Ph.Int.) since 1951. Originally, the pharmacopoeia covered every medication available for sale around the world, but, since 1975, has focused on providing standards for what the WHO describes as priority medicines of major health importance, including children's medications, essential medicines recommended by WHO disease programs, and medications evaluated by the Medicines Prequalification Programme. WHO pharmaceutical experts have developed the pharmacopoeia in consultation with WHO member states' drug regulation authorities, national drug quality control labs, and standard-setting organizations, as well as with WHO Centres and drug manufacturers. The thirteenth edition of the pharmacopoeia was published in 2025.

Bibliography

Birse, Mark. “The British Pharmacopoeia’s New Website – Setting the Standards.” MHRA Inspectorate, 14 Aug. 2015, mhrainspectorate.blog.gov.uk/2015/08/14/the-british-pharmacopoeias-new-website-setting-the-standards/. Accessed 10 Mar. 2026.

Brayfield, Alison. Martindale: The Complete Drug Reference. Pharmaceutical, 2014.

Bryan, Jenny. “Q&A: Providing Official Standards for UK Medicines and Pharmaceutical Substances—the British Pharmacopoeia.” The Pharmaceutical Journal, 28 Apr. 2016, pharmaceutical-journal.com/article/feature/qa-providing-official-standards-for-uk-medicines-and-pharmaceutical-substances-the-british-pharmacopoeia. Accessed 10 Mar. 2026.

“Building Trust for over 200 Years: A Timeline of USP.” U.S. Pharmacopeia, www.usp.org/200-anniversary/usp-timeline. Accessed 10 Mar. 2026.

Cairns, Donald. Essentials of Pharmaceutical Chemistry. Pharmaceutical, 2012.

Cartwright, A. C. The British Pharmacopoeia, 1864 to 2014: Medicines, International Standards and the State. Ashgate, 2015.

Cogliandro, Eugenia. “Ph. Eur. and Other Pharmacopoeias: Harmonization.” Workshop on Pharmacopeias: Overview, Uses, and Related Activities – A Guide Towards a Correct Use, University of Pavia, 17 Nov. 2023, www.aifa.gov.it/documents/20142/1812131/2023-11-17_Eugenia-Cogliandro_Pavia.pdf. Accessed 10 Mar. 2026.

Davies-Coleman, Mike. “Medicines from Marine Invertebrates.” School Science Review, vol. 93, no. 343, 2011, pp. 27–30.

Ginat, Daniel T., et al. Neuroimaging Pharmacopoeia. Springer, 2015.

"Health Products Policy and Standards." World Health Organization, www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/international-pharmacopoeia. Accessed 16 Mar. 2026.

"International Pharmacopoeia." Prequalification of Medical Products, WHO, extranet.who.int/prequal/medicines/international-pharmacopoeia. Accessed 16 Mar. 2026.

The International Pharmacopoeia. 13th ed., World Health Organization, 2025.

Menzies-Trull, Christopher. Herbal Medicine: Keys to Physiomedicalism Including Pharmacopoeia. Faculty of Physiomedical Herbal Medicine, 2013.

Morris, Louis A., and Nancy J. Olins. “Utility of Drug Leaflets for Elderly Consumers.” American Journal of Public Health, vol. 74, no. 2, 1984, pp. 157–158.